Oct 20 (Reuters) - UK's MHRA:
UK'S MHRA: UK MARKETING AUTHORISATION FOR IXCHIQ CHIKUNGUNYA VACCINE WITHDRAWN FOLLOWING SAFETY REVIEW
UK'S MHRA: MHRA HAS CONCLUDED THAT BENEFIT-RISK BALANCE FOR IXCHIQ CHIKUNGUNYA VACCINE IS NO LONGER CONSIDERED FAVOURABLE
Further company coverage: VLS.PA
Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk
